Company news

Arrowhead Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Arrowhead Presents New Clinical Data on ARO-APOC3 at AHA 2021

November 14, 2021

Arrowhead Collaborator Presents Phase 2b Clinical Data from REEF-1 Study in Patients with Chronic Hepatitis B Infection

November 14, 2021

Arrowhead Presents Additional Clinical Data on Investigational ARO-HSD Treatment at AASLD Liver Meeting

November 11, 2021

Arrowhead Presents Additional Clinical Data on Investigational ARO-AAT Treatment at AASLD Liver Meeting

November 11, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Year End Results

October 31, 2021

Arrowhead Pharmaceuticals to Participate in Upcoming November 2021 Conferences

October 31, 2021

Arrowhead Files for Regulatory Clearance to Begin Phase 1/2a Study of ARO-C3 for Treatment of Complement Mediated Diseases

October 24, 2021

Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinar on ARO-C3 for Treatment of Complement Mediated Diseases

October 11, 2021

Arrowhead Pharmaceuticals Initiates Phase 2b Study of ARO-APOC3 for Treatment of Mixed Dyslipidemia

September 29, 2021

Arrowhead Pharmaceuticals to Participate in Upcoming October 2021 Conferences

September 28, 2021

Arrowhead Earns $10 Million Phase 1 Milestone Payment

September 27, 2021

Arrowhead Pharmaceuticals to Participate in Upcoming September 2021 Conferences

August 31, 2021

Arrowhead Pharmaceuticals Reports Fiscal 2021 Third Quarter Results

August 4, 2021

Arrowhead Pharmaceuticals Receives Breakthrough Therapy Designation from U.S. FDA for ARO-AAT for the Treatment of Alpha-1 Antitrypsin Deficiency Associated Liver Disease

July 28, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Third Quarter Results

July 13, 2021

Arrowhead Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

July 13, 2021

Arrowhead Announces Positive Interim Results from Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma

July 5, 2021

Arrowhead Pauses ARO-ENaC Phase 1/2 Clinical Study

July 1, 2021

Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-ANG3 for Treatment of Mixed Dyslipidemia

June 29, 2021

Arrowhead Presents Additional Clinical Data on Investigational ARO-AAT Treatment in Patients with Alpha-1 Liver Disease at EASL International Liver Congress

June 25, 2021

Arrowhead Presents Preclinical Data on ARO-DUX4 at FSHD Society International Research Congress

June 24, 2021

Arrowhead Presents Positive Interim Clinical Data on ARO-HSD Treatment in Patients with Suspected NASH at EASL International Liver Congress

June 22, 2021

Arrowhead Pharmaceuticals and Horizon Therapeutics Announce Collaboration to Develop RNAi Therapeutic for Uncontrolled Gout

June 20, 2021

Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-APOC3 for Treatment of Severe Hypertriglyceridemia

June 2, 2021

Arrowhead Pharmaceuticals to Participate in Upcoming Conferences

June 1, 2021

Arrowhead Earns $10 Million Option Exercise Fee

May 17, 2021

Arrowhead Pharmaceuticals Reports Fiscal 2021 Second Quarter Results

May 3, 2021

Arrowhead Announces Improvement in Fibrosis after ARO-AAT Treatment in Patients with Alpha-1 Liver Disease

April 27, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results

April 15, 2021

Arrowhead Announces ARO-DUX4 as First Muscle Targeted RNAi Candidate Using TRiMTM Platform

April 14, 2021

Arrowhead Pharmaceuticals Files IND to Begin Phase 2b Study of ARO-APOC3 in Patients with Severe Hypertriglyceridemia

February 28, 2021

Arrowhead Pharmaceuticals Reports Fiscal 2021 First Quarter Results

February 3, 2021

Arrowhead Pharmaceuticals Files IND for Phase 2b Study of ARO-ANG3 for Treatment of Mixed Dyslipidemia

January 24, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 First Quarter Results

January 18, 2021

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)

December 6, 2020

NeuBase Therapeutics Announces Appointment of Curt Bradshaw, Ph.D. as Chief Scientific Officer

December 1, 2020

Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda

November 24, 2020

Arrowhead Pharmaceuticals Reports Fiscal 2020 Year End Results

November 22, 2020

Arrowhead Presents New Clinical Data on Cardiometabolic Pipeline at AHA 2020

November 12, 2020

Arrowhead Interim Clinical Data Demonstrate ARO-AAT Treatment Improved Multiple Biomarkers of Alpha-1 Liver Disease

November 12, 2020

Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinars on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3

November 3, 2020

Arrowhead Pharmaceuticals to Webcast Fiscal 2020 Year End Results

November 1, 2020

Takeda and Arrowhead Collaborate to Co-Develop and Co-Commercialize ARO-AAT for Alpha-1 Antitrypsin-Associated Liver Disease

October 7, 2020

Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conference

September 29, 2020

Arrowhead ARO-AAT Phase 2 Interim Results in Patients with Alpha-1 Liver Disease Demonstrate Improvements in Key Parameters after Six Months of Treatment

September 15, 2020

Arrowhead Pharmaceuticals to Participate in Upcoming September 2020 Conferences

September 7, 2020

Arrowhead Pharmaceuticals Appoints Oye Olukotun to Board of Directors

September 7, 2020

Arrowhead Presents Positive New Phase 1/2 Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 at European Society of Cardiology Congress 2020

August 30, 2020

Arrowhead and Collaborator Janssen Present Phase 2 Clinical Data on Investigational Hepatitis B Therapeutic JNJ-3989 at The Digital Liver Congress

August 27, 2020

Arrowhead Pharmaceuticals to Participate in Upcoming August 2020 Conferences

August 17, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 19 calls. Every call is listed under its year.

Decks

The 5 newest of 16 decks. Every deck is listed under its year.